Filing Details
- Accession Number:
- 0001144204-14-049047
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-08-12 21:03:45
- Reporting Period:
- 2014-08-09
- Filing Date:
- 2014-08-12
- Accepted Time:
- 2014-08-12 21:03:45
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1270073 | Intercept Pharmaceuticals Inc | ICPT | Pharmaceutical Preparations (2834) | 223868459 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1559537 | Paolo Fundaro | C/O Intercept Pharmaceuticals, Inc. 450 W. 15Th Street, Suite 505 New York NY 10011 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2014-08-09 | 324 | $0.00 | 9,127 | No | 4 | M | Direct | |
Common Stock | Disposition | 2014-08-11 | 324 | $239.49 | 8,803 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Restricted Stock Units | Disposition | 2014-08-09 | 324 | $0.00 | 324 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | M | Direct |
Footnotes
- The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 5, 2013.
- Conversion of restricted stock units ("RSU") to shares of common stock on a one-for one-basis.
- On November 16, 2012, the reporting person was granted 2,596 RSUs. The RSUs reported as having been disposed and the corresponding shares reported as having been acquired, representing 12.5% of the shares underlying the RSUs, became vested on August 9, 2014, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan.